VRDN-006 — Full data
2026
Viridian anticipates sharing development plans for VRDN-006 in 2026.Source filing
VRDN biotech catalysts & pipeline
VIRIDIAN THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
VRDN-006 — Regulatory decision
2026
We expect to communicate development plans for VRDN-006 in 2026.Source filing
VRDN-008 — Topline data
H2 2026
A phase 1 clinical trial assessing VRDN-008 in healthy volunteers is currently ongoing with data on track for the second half of 2026.Source filing
anti-thyroid-stimulating hormone receptor antibody — IND submission
Q4 2026
Viridian plans to submit an Investigational New Drug (IND) application in Q4 2026.Source filing
anti-TSHR product candidate — IND submission
Q4 2026
Anticipated IND Q4 2026Source filing
TSHR antibody — IND submission
Q4 2026
Viridian plans to submit an Investigational New Drug (IND) application in Q4 2026 and expects to develop this program in TED and Graves' disease.Source filing
elegrobart — NDA/BLA submission
Q1 2027
- Elegrobart, potentially the first subcutaneous autoinjector for the treatment of TED, on track for BLA submission Q1 2027 -Source filing